Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer

JCO Precis Oncol. 2022 Nov:6:e2200382. doi: 10.1200/PO.22.00382.

Michael L Cheng^{1

2

3}, Jessica K Lee⁴, Rachit Kumar⁵, Harry Klein⁶, Kira Raskina⁴, Alexa B Schrock⁴, Kesi S Michael^{1

7}, Tali Mazor⁶, Ethan Cerami⁶, Geoffrey R Oxnard⁴, David Liu², Himisha Beltran², Lynette M Sholl⁸, Mizuki Nishino^{9

10}, Pasi A Jänne^{1

2

11}

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
³ Present address: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
⁴ Foundation Medicine, Cambridge, MA.
⁵ Harold Alfond Center for Cancer Care, MaineHealth, Augusta, MA.
⁶ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
⁷ Present address: Foundation Medicine, Cambridge, MA.
⁸ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
⁹ Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
¹⁰ Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
¹¹ Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA.

No abstract available

Publication types